Skip to main content
Publications
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho C, Reynolds M , Sherif B , Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study . Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030
Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D , Bartsch J , Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial . Eur J Cancer. 2021 Jul 14;154:138-46.
Garcia Del Blanco B, Otaegui I, Rodriguez-Palomares JF, Bayes-Genis A, Fernandez-Nofrerias E, Vilalta Del Olmo V, Carrillo X, Ibanez B, Worner F, Casanova J, Pueo E, Gonzalez-Juanatey JR, Lopez-Pais J, Bardaji A, Bonet G, Fuertes M, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Barba I, Gomez-Talavera S, Marti G, Serra B, Bellera N, Ojeda-Ramos M, Cuellar H, Valente F, Carmona MA, Miro-Casas E, Marsal JR , Sambola A, Lidon RM, Baneras J, Elizaga J, Padilla F, Barrabes JA, Hausenloy DJ, Ferreira-Gonzalez I, Garcia-Dorado D. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI) . Basic Res Cardiol. 2021 Jan 25;116(1):4. doi: 10.1007/s00395-021-00842-2
Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, Garcia-Albeniz X , Maurel J, Vilella R. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients . Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008
Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X , Jares P, Castells A, Lozano JJ, Rosell R, Maurel J. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy . Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019